Pfizer Market Cap 2010-2024 | PFE

Pfizer market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of July 26, 2024 is $171.02B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $171.018B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $780.463B 112.80
Novo Nordisk (NVO) Denmark $573.776B 44.09
Johnson & Johnson (JNJ) United States $384.202B 15.23
AbbVie (ABBV) United States $321.688B 17.02
Merck (MRK) United States $318.754B 57.99
AstraZeneca (AZN) United Kingdom $243.454B 21.69
Novartis AG (NVS) Switzerland $224.697B 15.61
Sanofi (SNY) $134.488B 12.73
Innoviva (INVA) United States $1.136B 7.98